Clinical Trial Update: HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). [Phase 2]

View source ↗

Summary

The document reports an ongoing Phase 2 clinical trial evaluating HVA for newly diagnosed mixed-phenotype acute leukemia (MPAL), with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Phenotype Acute Leukemia

Drugs mentioned

• HVA

Snippet

Sponsor: Guangdong Second Provincial General Hospital | Conditions: Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Status: ENROLLING_BY_INVITATION